BrightSpring Health Services (BTSG) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BrightSpring Health Services (BTSG) has outperformed GeneDx (WGS) over the past year, gaining 120.4% versus a loss of 44.8%. BrightSpring Health Services is the larger company by market cap ($12.60 billion vs $2.02 billion), about 6.2 times the size, while GeneDx is growing revenue faster (+40.0% vs +28.2%). On valuation, BrightSpring Health Services trades at a lower forward P/E (27.9x vs 56.5x for GeneDx).
BrightSpring Health Services converts more of its revenue into profit, with a net margin of 1.5% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BTSG | WGS |
|---|---|---|
| Share price | $63.66 | $67.73 |
| Market cap | $12.60B | $2.02B |
| 1-day change | -0.22% | -1.17% |
| YTD return | +69.99% | -47.92% |
| 1-year return | +120.35% | -44.80% |
| 5-year return | — | -73.65% |
| P/E ratio (TTM) | 56.34 | — |
| Forward P/E | 27.94 | 56.51 |
| EPS (TTM) | $1.13 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.91B | $427.54M |
| Revenue growth (YoY) | +28.18% | +39.97% |
| Net income (latest FY) | $190.67M | $-21.02M |
| Gross margin | 11.76% | 69.74% |
| Operating margin | 2.29% | -3.06% |
| Net margin | 1.48% | -4.92% |
| 52-week high | $73.75 | $170.87 |
| 52-week low | $27.30 | $32.21 |
| Distance from 52-week high | -13.68% | -60.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.00% | +38.05% |
| Average volume | 3.19M | 730.21K |
| Shares outstanding | 197.86M | 29.82M |
| Employees | 23,500 | 1,300 |
| Sector | Healthcare | Health Care |
| Industry | Health Information Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BrightSpring Health Services is about 6.2 times larger than GeneDx by market value ($12.60B vs $2.02B).
- BTSG has outperformed WGS by 165.1 percentage points over the past year.
- BrightSpring Health Services is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- GeneDx grew revenue faster in its latest fiscal year (+39.97% vs +28.18%).
- The two companies sit in different sectors: BrightSpring Health Services in Healthcare and GeneDx in Health Care.
About BrightSpring Health Services
BTSG stock →BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States.
Healthcare · Health Information Services · 23,500 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
BTSG vs WGS FAQ
Which is bigger, BrightSpring Health Services or GeneDx?
BrightSpring Health Services (BTSG) is larger, with a market capitalization of $12.60B compared with $2.02B for GeneDx (WGS).
Which stock has performed better over the past year, BTSG or WGS?
BTSG returned +120.35% over the past 12 months, compared with -44.80% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are BrightSpring Health Services and GeneDx in the same industry?
No. BrightSpring Health Services is in the Healthcare sector, while GeneDx is in Health Care.